It has been granted a 'Notice of Approval for Clinical Trial of Drugs' issued by the
The Group always puts focus on the R&D of innovative products and advanced technologies, and adopts the strategy of 'global expansion and dual-cycle operation', continuing to increase its investment in the world-class innovative products and advanced technologies to meet unmet clinical needs. The Group has already predicted that anti-virus and anti-infection may become one of the key focuses to counter diseases that pose a great threat to human health following malignant tumor, and thus, the Group sets anti-virus and anti-infection as one of the focus areas in strategic planning. STC3141 has now completed a Phase Ia clinical trial of healthy volunteers in
Sepsis, commonly known as blood poisoning, is an immune system disorder caused by infection, which can lead to life-threatening organ dysfunction. It is a common fatal complication of patients with tumors and severe infections such as burns, trauma and major surgery. Sepsis affects more than 31.5 million people worldwide each year, of which over 19.4 million patients are with severe sepsis. ARDS is a non-cardiogenic clinical syndrome characterized by progressive dyspnea and refractory hypoxemia, which leads to hypoxia and respiratory distress. According to a survey of nearly 30,000 patients in 459 intensive care units ('ICUs') in 50 countries, the prevalence of ARDS is 10.4% among critically ill patients. Currently there are limited access to treatment for ARDS, with an overall mortality rate of 34% in hospital and 60% in severe cases. In the COVID-19 pandemic, ARDS and sepsis are also important causes of death. There is a clear relevance between the two pathogenic mechanisms. However, there is a lack of drugs targeted for sepsis in the market, indicating an urgent clinical demand and tremendous market prospect.
With clear therapeutic mechanism, STC3141 is used to treat sepsis by reversing organ damage which is caused by the body's excessive immune response through neutralizing extracellular histones and neutrophil trapping nets. The results of STC3141 were published in the top academic journal 'Nature Communications' in
The Board of
Contact:
Email: ir@chinagrandpharm.com
Web: www.chinagrandpharm.com
(C) 2021 Electronic News Publishing, source